Jan Smeıtınk

31.4k total citations · 3 hit papers
348 papers, 22.3k citations indexed

About

Jan Smeıtınk is a scholar working on Molecular Biology, Clinical Biochemistry and Physiology. According to data from OpenAlex, Jan Smeıtınk has authored 348 papers receiving a total of 22.3k indexed citations (citations by other indexed papers that have themselves been cited), including 304 papers in Molecular Biology, 183 papers in Clinical Biochemistry and 29 papers in Physiology. Recurrent topics in Jan Smeıtınk's work include Mitochondrial Function and Pathology (253 papers), Metabolism and Genetic Disorders (183 papers) and ATP Synthase and ATPases Research (147 papers). Jan Smeıtınk is often cited by papers focused on Mitochondrial Function and Pathology (253 papers), Metabolism and Genetic Disorders (183 papers) and ATP Synthase and ATPases Research (147 papers). Jan Smeıtınk collaborates with scholars based in Netherlands, Germany and United States. Jan Smeıtınk's co-authors include Peter H.G.M. Willems, Werner J.H. Koopman, Richard J. Rodenburg, Leo Nijtmans, Lambert P. van den Heuvel, Frans J.M. Trijbels, Kees Brinkman, Lambert van den Heuvel, Ron A. Wevers and Lambertus P. van den Heuvel and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Jan Smeıtınk

344 papers receiving 21.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Second Common Mutation in the Methylenetetrahydrofolate Reductase Gene: An Additional Risk Factor for Neural-Tube Defects?

1998 1.3k citations Jan Smeıtınk, Lambert P. van den Heuvel et al. profile →
Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy

1999 677 citations Jan Smeıtınk et al. profile →
Adverse effects of reverse transcriptase inhibitors

1998 671 citations Jan Smeıtınk et al. profile →

Peers

Countries citing papers authored by Jan Smeıtınk

Since Specialization

Citations

This map shows the geographic impact of Jan Smeıtınk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Smeıtınk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Smeıtınk more than expected).

Fields of papers citing papers by Jan Smeıtınk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Smeıtınk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Smeıtınk. The network helps show where Jan Smeıtınk may publish in the future.

Co-authorship network of co-authors of Jan Smeıtınk

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Smeıtınk. A scholar is included among the top collaborators of Jan Smeıtınk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Smeıtınk. Jan Smeıtınk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase 2b program with sonlicromanol in patients with mitochondrial disease due to m.3243A>G mutation 2024 ·Brain ·Jan Smeıtınk, Jan van Es, (unknown), Mirian C. H. Janssen, Thomas Klopstock, Gráinne S. Gorman, (unknown), (unknown), Chris J. Edgar, Evertine J. Abbink, Rob van Maanen, Oksana Pogoryelova, Claudia Stendel, (unknown), Ivan Karin, Medha Munshi, Anne Kümmel, (unknown), C.M. Verhaak, G. Herma Renkema	3
2	Variants in NGLY1 lead to intellectual disability, myoclonus epilepsy, sensorimotor axonal polyneuropathy and mitochondrial dysfunction 2020 ·Clinical Genetics ·(unknown), Saskia B. Wortmann, Charlotte A. Haaxma, Peter M. van Hasselt, Nicole I. Wolf, Yvonne Hendriks, Benno Küsters, (unknown), (unknown), Werner J.H. Koopman, Liesbeth T. Wintjes, (unknown), Maaike de Vries, Dirk J. Lefeber, Jan Smeıtınk, Richard J. Rodenburg	23
3	Quantification of gait in children with mitochondrial disease 2018 ·Journal of Inherited Metabolic Disease ·Saskia Koene, Niki M. Stolwijk, (unknown), Maaike C. de Vries, Lonneke de Boer, Mirian C. H. Janssen, Imelda J. M. de Groot, Jan Smeıtınk	0
4	Outcome measures for children with mitochondrial disease: consensus recommendations for future studies from a Delphi‐based international workshop 2018 ·Journal of Inherited Metabolic Disease ·Saskia Koene, (unknown), Enrico Bertini, Cecilia Jimenez‐Moreno, (unknown), Imelda J. M. de Groot, Robert McFarland, Sumit Parikh, Shamima Rahman, (unknown), J Zeman, Anjo J.W.M. Janssen, Jan Smeıtınk	21
5	KH176 Safeguards Mitochondrial Diseased Cells from Redox Stress-Induced Cell Death by Interacting with the Thioredoxin System/Peroxiredoxin Enzyme Machinery 2018 ·Scientific Reports ·Julien Beyrath, Mina Pellegrini, G. Herma Renkema, (unknown), (unknown), Peter van Zandvoort, Petra van den Broek, (unknown), Pierre Eftekhari, Jan Smeıtınk	57
6	Mining for mitochondrial mechanisms: Linking known syndromes to mitochondrial function 2017 ·Clinical Genetics ·(unknown), Jan Smeıtınk, Richard J. Rodenburg	6
7	Quantification of gait in mitochondrial m.3243A > G patients: a validation study 2017 ·Orphanet Journal of Rare Diseases ·(unknown), Saskia Koene, Jan T. Groothuis, Paul de Laat, Mirian C. H. Janssen, Jan Smeıtınk	4
8	Radboud Centre for Mitochondrial Medicine Pediatric MRI score 2016 ·Mitochondrion ·(unknown), Bożena Góraj, Cheuk‐Wing Fung, (unknown), Lonneke de Boer, Saskia Koene, Jan Smeıtınk	2
9	Mitochondrial Retinal Dystrophy Associated with the m.3243A>G Mutation 2013 ·Ophthalmology ·Paul de Laat, Jan Smeıtınk, Mirian C. H. Janssen, Jan E.E. Keunen, Camiel J.F. Boon	61
10	Clinical features and heteroplasmy in blood, urine and saliva in 34 Dutch families carrying the m.3243A > G mutation 2012 ·Journal of Inherited Metabolic Disease ·Paul de Laat, Saskia Koene, (unknown), Richard J. Rodenburg, Mirian C. H. Janssen, Jan Smeıtınk	105
11	A mutation in the FAM36A gene, the human ortholog of COX20, impairs cytochrome c oxidase assembly and is associated with ataxia and muscle hypotonia 2012 ·Human Molecular Genetics ·Radek Szklarczyk, Bas F.J. Wanschers, Leo Nijtmans, Richard J. Rodenburg, Johannes Zschocke, Nicola Dikow, Mariël A.M. van den Brand, (unknown), Christian Gilissen, Joris A. Veltman, Marco Nooteboom, Werner J.H. Koopman, Peter H.G.M. Willems, Jan Smeıtınk, Martijn A. Huynen, Lambertus P. van den Heuvel	69
12	A catalytic defect in mitochondrial respiratory chain complex I due to a mutation in NDUFS2 in a patient with Leigh syndrome 2011 ·Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease ·Lock Hock Ngu, Leo Nijtmans, Felix Distelmaier, Hanka Venselaar, Sjenet E. van Emst‐de Vries, Mariël A.M. van den Brand, (unknown), Liesbeth T. Wintjes, Peter H.G.M. Willems, Lambertus P. van den Heuvel, Jan Smeıtınk, Richard J. Rodenburg	27
13	Isolated deficiencies of OXPHOS complexes I and IV are identified accurately and quickly by simple enzyme activity immunocapture assays 2008 ·Biochimica et Biophysica Acta (BBA) - Bioenergetics ·John H. Willis, Roderick Capaldi, Merei Huigsloot, Richard J. Rodenburg, Jan Smeıtınk, Michael F. Marusich	33
14	Partial complex I inhibition decreases mitochondrial motility and increases matrix protein diffusion as revealed by fluorescence correlation spectroscopy 2007 ·Biochimica et Biophysica Acta (BBA) - Bioenergetics ·Werner J.H. Koopman, Mark A. Hink, Sjoerd Verkaart, Henk-Jan Visch, Jan Smeıtınk, Peter H.G.M. Willems	25
15	Pathological Mutations of the Human NDUFS4 Gene of the 18-kDa (AQDQ) Subunit of Complex I Affect the Expression of the Protein and the Assembly and Function of the Complex 2003 ·Journal of Biological Chemistry ·Salvatore Scacco, Vittoria Petruzzella, (unknown), R. Vergari, Rosanna Tamborra, Damiano Panelli, Lambert P. van den Heuvel, Jan Smeıtınk, Sergio Papa	114
16	Mitochondrial oxidative phosphorylation system assembly in man: recent achievements 2001 ·Current Opinion in Neurology ·Marieke J. H. Coenen, Lambert P. van den Heuvel, Jan Smeıtınk	23
17	A review of biochemical and molecular genetic aspects of tyrosine hydroxylase deficiency including a novel mutation (291delC) 1999 ·Journal of Inherited Metabolic Disease ·Ron A. Wevers, J.F. de Rijk-van Andel, Chad A. Brautigam, (unknown), Lambert P.W.J. van den Heuvel, Gerry C. H. Steenbergen‐Spanjers, Jan Smeıtınk, G. F. Hoffmann, F.J.M. Gabreëls	38
18	Leigh syndrome associated with a mutation in the NDUFS7 (PSST) nuclear encoded subunit of complex I 1999 ·Annals of Neurology ·Ralf Triepels, Lambertus P. van den Heuvel, Jan Loeffen, Carin A. F. Buskens, Roel Smeets, (unknown), (unknown), Edwin C.M. Mariman, Frits A. Wijburg, P. G. Barth, J. M. F. Trijbels, Jan Smeıtınk	164
19	Treatment and molecular analysis of neonatal carnitine palmitoyltransferase II deficiency. 1999 ·Pediatric Research ·Jan Smeıtınk, B. A. Semmekrot, (unknown), H.R. Scholte, Lambertus P. van den Heuvel, Carla Costa, U. Wendel, W. Ruitenbeek, (unknown), (unknown), (unknown), Jennifer Jager, (unknown), (unknown), R. C. A. Sengers, C. Jakobs, J. M. F. Trijbels	2
20	Nephrotoxicity associated with ifosfamide 1988 ·European Journal of Pediatrics ·Jan Smeıtınk, (unknown), (unknown), R. J. J. Lippens	46

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact